Wave Life Sciences Plans to Integrate WVE-007 Maintenance and Tirzepatide Combination Trials

PUBT · 1d ago
Wave Life Sciences Plans to Integrate WVE-007 Maintenance and Tirzepatide Combination Trials
  • Wave Life Sciences will present Phase 1 results for obesity candidate WVE-007 at ObesityWeek on Nov. 15, 2026.
  • Fat loss without lean mass loss persisted for one year in the highest-baseline-BMI cohort; higher baseline adiposity was associated with greater benefit.
  • WVE-007 remained generally well tolerated, with no drug-related serious adverse events or treatment discontinuations.
  • Six-month Phase 2a monotherapy data in participants with higher BMI and adiposity are expected in 2027, including body composition and liver fat assessments.
  • A planned integration of the maintenance study into the ongoing WVE-007/tirzepatide combination trial aims to accelerate data delivery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130830PRIMZONEFULLFEED9877074) on November 13, 2026, and is solely responsible for the information contained therein.